Two 12-week phase 3 pivotal trials evaluated the efficacy and tolerability of Tapinarof cream 1% once daily in adults with mild-to-severe plaque psoriasis, demonstrating significant efficacy compared to the vehicle. Patients completing the 12-week treatment were eligible for 40 weeks of open-label tapinarof based on their Physician Global Assessment score in PSOARING 3, with a 4-week follow-up period. Among the 763 eligible patients enrolled, 78.5% completed the Patient Satisfaction Questionnaire, revealing that most patients experienced continued and durable improvements in health-related quality of life, with high rates of satisfaction and positive perceptions of tapinarof cream, as indicated by Dermatology Life Quality Index scores and responses to the Patient Satisfaction Questionnaire.

These results underscore the potential benefits of tapinarof cream 1% once daily in managing psoriasis symptoms and highlight the importance of patient-reported outcomes in assessing treatment efficacy and satisfaction.

Reference: Bagel J, Gold LS, Del Rosso J, et al. Tapinarof cream 1% once daily for the treatment of plaque psoriasis: Patient-reported outcomes from the PSOARING 3 trial. J Am Acad Dermatol. 2023 Nov;89(5):936-944. doi: 10.1016/j.jaad.2023.04.061. Epub 2023 May 10. PMID: 37172733.